Amyotrophic lateral sclerosis (ALS) is a rare, progressing disease in which motor neurons degenerate or die diminishing the signals that control muscle function.
The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.
The REFALS trial is studying the effects of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS).
Orion aims to build well-being in ALS by developing effective new treatments to help patients manage their illness and improve their quality of life.
The beginning and progression of ALS symptoms vary between people. The treatment is planned by a multi-professional team in cooperation with the patient. The patients’ families need support as well.
